Baldini, Capucine
Danlos, Francois-Xavier
Varga, Andreea
Texier, Matthieu
Halse, Heloise
Mouraud, Severine
Cassard, Lydie
Champiat, Stéphane
Signolle, Nicolas
Vuagnat, Perrine
Martin-Romano, Patricia
Michot, Jean-Marie
Bahleda, Rastislav
Gazzah, Anas
Boselli, Lisa
Bredel, Delphine
Grivel, Jonathan
Mohamed-Djalim, Chifaou
Escriou, Guillaume
Grynszpan, Laetitia
Bigorgne, Amelie
Rafie, Saloomeh
Abbassi, Alae
Ribrag, Vincent
Postel-Vinay, Sophie
Hollebecque, Antoine
Susini, Sandrine
Farhane, Siham
Lacroix, Ludovic
Parpaleix, Aurelien
Laghouati, Salim
Zitvogel, Laurence
Adam, Julien
Chaput, Nathalie
Soria, Jean-Charles
Massard, Christophe
Marabelle, Aurelien
Funding for this research was provided by:
Boehringer Ingelheim
Merck Sharp and Dohme
MSD Life Science Foundation, Public Interest Incorporated Foundation
Article History
Received: 31 December 2021
Accepted: 17 June 2022
First Online: 7 July 2022
Declarations
:
: Studies were conducted in accordance with the Declaration of Helsinki and approved by local and multicenter research ethical committees.
: Not applicable.
: BI & MSD are partly funding the PEMBIB trial and its ancillary analysis. They had a right of first glance at the data reported but could not modify or influence the results reported in the manuscript neither their interpretation. Gustave Roussy as the sponsor and his investigators remain independent from BI & MSD for the data analysis, interpretation, and publication of the PEMBIB trial. Over the last 5 years, AM provided consulting work to BI for a project not related to the PEMBIB trial, participated to a scientific advisory board with MSD on a topic not related to the PEMBIB trial, has been a principal investigator for MSD-sponsored clinical trials not related to the PEMBIB trial and received a research grant from Fondation MSD Avenir that was partly funding some lab technician time and biological assays that were used for the ancillary analysis of the PEMBIB trial. JCS have shares in Gritstone bio and Relay Therapeutics, is Board of Director at Hookipa Pharmaceuticals and is Full time employee at Amgen since August 2021. As part of members of the DITEP CB, AV, SC, PV, PM-R, J-MM, RB, AG, VR, SP-V, AH and CM are Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc., Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd., Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd., Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd., Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A. S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor. They benefit from research Grants from Astrazeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi and non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. The other authors declare no conflicts of interest.